Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2007

View Archived Issues

Chugai reports domestic and overseas developments for 2006

Novel metabolic drugs described in recent patent literature

Alitretinoin demonstrates efficacy in chronic hand dermatitis

Phase III results demonstrate efficacy of M6G in patients with postoperative pain

Vernakalant (i.v.) NDA accepted for review

Preclinical studies show CF-102 active against hepatitis B virus

BTG inlicenses opioid agonist for postoperative pain

Roche grants GSK rights to non-prescription orlistat

ElSohly Laboratories licenses GelSite technology to formulate anticancer drug

University of Texas researchers study chlamydial prevention vaccine

Metabolic to announce phase IIb results for AOD-9604

Tripep partners with Kringle on ChronSeal

Entelos and Organon extend rheumatoid arthritis collaboration

Ecopia BioSciences and Caprion advance merger plans

ICX-SKN skin graft substitute studied in phase I trial

CAM-2028 cleared to begin phase II oral mucositis study

Xanthine oxidoreductase: a novel target for obesity and metabolic diseases

Telavancin NDA accepted for review

Bone regeneration seen with tissue repair cells

GVAX cancer vaccine safe after stem cell transplant in acute myeloid leukemia patients

Results with Favld immunotherapy promising in non-Hodgkin's lymphoma

ZIO-101 well tolerated in phase I study in multiple myeloma

Heat shock protein 90 inhibitor shows promise for Alzheimer's disease in preclinical studies

Novel agents for cardiovascular disorders disclosed in Vertex and Merck Frosst patents

AMR and Bristol-Myers Squibb patent discloses new agents for ADHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...